Breast Cancer

After a diagnosis of stage 3 breast cancer at age 32, Moana Papa embraced advocacy, traveling from her home in New Zealand to the San Antonio Breast Cancer Symposium to bring information back to her community.

Obese women with breast cancer are at higher risk for recurrence and death, but new findings suggest it may depend on cancer subtype.

In the NeoSphere study, various combinations of a new HER2-targeted agent called pertuzumab, Herceptin and chemothery were studied in early-stage breast cancer patients with encouraging results.

After breast cancer, clinical sexologist Sueann Mark, PhD, developed a program to help survivors regain their sexuality after cancer.

New studies start to pinpoint the best strategy for treating HER2-positive breast cancer before surgery and lay the groundwork for future clinical trials.

Two studies presented at SABCS offer a better understanding of what to do with the information sentinel lymph nodes provide.

When faced with breast cancer as a young Jewish woman, Rochelle Shoretz learned that her heritage, including its risk of cancer-associated mutations, brought up unique issues, which led her to create Sharsheret, a nonprofit organization.

Findings from the long-awaited AZURE trial show Zometa may prevent recurrence, but not for everyone.

Not only is weight training safe, but for women who have had lymph node removal due to breast cancer surgery, it also may reduce the risk of lymphedema by about a third.

Wanda Brown, 54, is celebrating six years of survivorship this month, and her knowledge of the disease is a far cry from that day back in 2004 when she found the lump in her breast.

Trial shows CT scans may save lives of heavy smokers.

The latest in cancer prevention, diagnosis & treatment

Helping bones stay strong after cancer.

A recap of the 2008 San Antonio Breast Cancer Symposium.

Every woman with a mutated BRCA1 or BRCA2 gene should have their ovaries removed to lower their risk of ovarian cancer, said Susan Domchek, MD, one of the educational sessions speakers at the 2010 SABCS.

News of Elizabeth Edwards' death heightens a sense of urgency at the 33rd annual San Antonio Breast Cancer Symposium among patients, survivors and advocates.

New research shows some metastatic breast cancer patients could be receiving the wrong treatment.

A recent and rare look at long-term lung cancer survivors shows breathlessness among them is persistent and common.

The latest in cancer prevention, diagnosis & treatment.

Adherence to oral hormone therapy for breast cancer patients is important, but non-compliance, and its consequences, are just now being recognized.

PARP inhibitors continue to look “promising.”

For those weighing whether to get their BRCA mutation status checked, the potential promise of the PARP inhibitors shouldn’t tip the balance—yet.

Metformin, a drug commonly used in the treatment of type 2 diabetes, is showing promise in the treatment of certain types of hormone-stimulated cancers, such as breast cancer and prostate cancer.

Only a few years ago, Bevelle and Edwards would have automatically received the same treatment. Not so today.

A new chemotherapy drug, called eribulin, extended survival by two and a half months in patients with locally recurrent or metastatic breast cancer whose cancers continued to progress despite treatment with numerous other drugs.

Updates results from the STAR trial show Evista and tamoxifen have long-term breast cancer prevention effects.

Updates from the annual meeting of the American Society of Clinical Oncology.

A growing population of patients have emerged: long-term metastatic cancer survivors.

The latest in cancer prevention, diagnosis, and treatment.

Progress in lung cancer is likely to stem from targeted treatments.